CA
NZ
UK
AU
IND
US
Two searches found no company release, 8-K or published coverage dated November 9 or November 10, 2026 that explains the move, so no catalyst is identified in published coverage. As general context, a gain above 100% in a clinical-stage biotech usually follows one of …
Searches found company announcements on platform launches and partnerships, but no release or filing dated November 9 or November 10, 2026, so no catalyst is identified in published coverage. As general context, moves of this size in micro-cap names often follow aPartnershipor product announcement, …
Searches found the reverse split, the offering andLeadershipchanges, including a new sole chief executive, but no release or filing dated November 9 or November 10, 2026, so no catalyst is identified in published coverage. As general context, restructured nano-caps often move on consolidation effects, …
Searches found only quote pages and a first-half 2026 loss report as costs rose, with no company release or filing dated November 9 or November 10, 2026, so no catalyst is identified in published coverage. As general context, small moves in thinly traded stocks …
No company release or filing dated November 9 or 10, 2026 was found in two searches, so no catalyst is identified in published coverage. The latest items located were dated September 30, 2026, when the company reported FDA pre-submission feedback supporting a 510(k) pathway …
Three lookups found no results release, trial update, financing or analyst action dated November 9 or 10, 2026, so no catalyst is identified in published coverage. The latest dated context located is the November 21, 2025 third-quarter report, when the stock rose 29% to …
Three lookups found no results release, dividend,Mergeror filing dated November 9 or 10, 2026, so no catalyst is identified in published coverage. Context located: the August 6, 2026 report showed second-quarterRevenueof USD 4.6 million versus USD 4.8 million,Operating Incomeof USD 0.7 million (15% of …
The catalyst is the company release headlined as third-quarter results with a reaffirmed 2026 outlook. Guidance calls for revenue of USD 1,940 million to USD 1,990 million, adjusted EBITDA of USD 205 million to USD 225 million, non-GAAP operating income of USD 145 million …
Key HighlightsHumacyte (NASDAQ:HUMA) closed at USD 0.5830 on Tuesday, November 10, 2026, up 28.08% from a calculated prior close of USD 0.4552, a gain of USD 0.1278 per share, among the session's top gainers.Volume reached 6.98 million shares at a relativeVolumeof 1.62, implying a …
The identified catalyst is the results beat and the higher 2026 outlook. Fourth-quarter guidance is revenue of USD 118 million to USD 122 million, up 6% to 9%, and adjusted EBITDA of USD 16 million to USD 20 million, a 14% to 16% margin. …
Please wait processing your request...